{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:36:47Z","timestamp":1761896207862},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T00:00:00Z","timestamp":1449792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00277-015-2570-1","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T23:28:41Z","timestamp":1449790121000},"page":"403-407","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Temsirolimus acts as additive with bendamustine in aggressive lymphoma"],"prefix":"10.1007","volume":"95","author":[{"given":"Anna-Katharina","family":"Zoellner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Weiglein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grit","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Christian","family":"Cieplik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,11]]},"reference":[{"issue":"2","key":"2570_CR1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1365-2141.2003.04761.x","volume":"124","author":"F Bertoni","year":"2004","unstructured":"Bertoni F, Zucca E, Cotter FE (2004) Molecular basis of mantle cell lymphoma. Br J Haematol 124(2):130\u2013140","journal-title":"Br J Haematol"},{"issue":"2","key":"2570_CR2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2141.2006.06378.x","volume":"136","author":"W Hiddemann","year":"2007","unstructured":"Hiddemann W et al (2007) Current management of follicular lymphomas. Br J Haematol 136(2):191\u2013202","journal-title":"Br J Haematol"},{"issue":"4","key":"2570_CR3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann A et al (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27(4):511\u2013518","journal-title":"J Clin Oncol"},{"issue":"1","key":"2570_CR4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","volume":"12","author":"R Zoncu","year":"2011","unstructured":"Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1):21\u201335","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2570_CR5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12(1):9\u201322","journal-title":"Cancer Cell"},{"issue":"4","key":"2570_CR6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","volume":"12","author":"SM Ansell","year":"2011","unstructured":"Ansell SM et al (2011) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 12(4):361\u2013368","journal-title":"Lancet Oncol"},{"issue":"4","key":"2570_CR7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.clml.2013.04.003","volume":"13","author":"B Coiffier","year":"2013","unstructured":"Coiffier B (2013) Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 13(4):351\u2013359","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2570_CR8","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/leu.2015.60","volume":"29","author":"G Hess","year":"2015","unstructured":"Hess G et al (2015) Safety and efficacy of temsirolimus in combination with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma. Leukemia 29(8):1695\u20131701","journal-title":"Leukemia"},{"key":"2570_CR9","first-page":"393","volume":"201","author":"M Schulze","year":"2014","unstructured":"Schulze M et al (2014) Temsirolimus recent results. Cancer Res 201:393\u2013403","journal-title":"Cancer Res"},{"key":"2570_CR10","unstructured":"Zoellner AK et al (2015) Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway. Leuk Lymphoma 1-8"},{"key":"2570_CR11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/1471-2407-13-308","volume":"13","author":"M Witzens-Harig","year":"2013","unstructured":"Witzens-Harig M et al (2013) A phase I\/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor temsirolimus added to standard therapy of rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-cell lymphoma\u2014the STORM trial. BMC Cancer 13:308","journal-title":"BMC Cancer"},{"issue":"21","key":"2570_CR12","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1158\/1078-0432.CCR-13-3172","volume":"20","author":"J Kawada","year":"2014","unstructured":"Kawada J et al (2014) mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Clin Cancer Res 20(21):5412\u20135422","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2570_CR13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.exphem.2007.12.008","volume":"36","author":"VY Yazbeck","year":"2008","unstructured":"Yazbeck VY et al (2008) Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 36(4):443\u2013450","journal-title":"Exp Hematol"},{"issue":"23","key":"2570_CR14","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G et al (2009) Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(23):3822\u20133829","journal-title":"J Clin Oncol"},{"issue":"1","key":"2570_CR15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcmd.2011.09.007","volume":"48","author":"C Visco","year":"2012","unstructured":"Visco C et al (2012) The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis 48(1):68\u201375","journal-title":"Blood Cells Mol Dis"},{"issue":"9873","key":"2570_CR16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210","journal-title":"Lancet"},{"issue":"9","key":"2570_CR17","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00277-015-2404-1","volume":"94","author":"M Becker","year":"2015","unstructured":"Becker M et al (2015) Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice. Ann Hematol 94(9):1553\u20131558","journal-title":"Ann Hematol"},{"issue":"9","key":"2570_CR18","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00277-014-2077-1","volume":"93","author":"A Garcia-Noblejas","year":"2014","unstructured":"Garcia-Noblejas A et al (2014) Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience. Ann Hematol 93(9):1551\u20131558","journal-title":"Ann Hematol"},{"issue":"19","key":"2570_CR19","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123(19):2944\u20132952","journal-title":"Blood"},{"key":"2570_CR20","doi-asserted-by":"crossref","DOI":"10.5962\/bhl.title.7320","volume-title":"Effect of more than one inhibitor. Enzymes and metabolic inhibitors. Vol. 1","author":"JL Webb","year":"1963","unstructured":"Webb JL (1963) Effect of more than one inhibitor. Enzymes and metabolic inhibitors. Vol. 1. Academic Press, New York"},{"issue":"11","key":"2570_CR21","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","volume":"31","author":"C Visco","year":"2013","unstructured":"Visco C et al (2013) Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 31(11):1442\u20131449","journal-title":"J Clin Oncol"},{"issue":"17","key":"2570_CR22","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","volume":"31","author":"K Ohmachi","year":"2013","unstructured":"Ohmachi K et al (2013) Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 31(17):2103\u20132109","journal-title":"J Clin Oncol"},{"issue":"5","key":"2570_CR23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2006.06210.x","volume":"134","author":"K Wanner","year":"2006","unstructured":"Wanner K et al (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134(5):475\u2013484","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2570-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2570-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2570-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T03:40:55Z","timestamp":1692157255000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2570-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,11]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["2570"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2570-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,11]]}}}